About US
Contact us
-
Novavax aims for billions of COVID-19 vaccine doses in 2021—more than enough to supply U.S.Some of the world’s largest biopharma companies are working to deliversafe and effectiveCOVID-19 vaccines, butat the same time, a much smallerbiotech has laid out its own big ambitions in the field.2020/8/11
-
Russia skips ahead in COVID vaccine race, triggering outcry over unproven 'Sputnik V' shotAs globalvaccine players rush to deliver COVID-19 vaccines, Russia shocked the world Tuesday with newsthatit had approved a locally developedinoculation. But that approval was based on skimpy data, a2020/8/11
-
Eisai will shift U.S. HQ to New Jersey 'bio-ecosystem' in move to boost oncology, neurology portfoliosJapanese drugmaker Eisai has established asolid foothold in the U.S. market and found some success with its Merck & Co.-partnered oncology med Lenvima. And alongside BIogen, it's in the FDA queue2020/8/10
-
Coronavirus tracker: Sinovac unveils midstage vaccine data; Daewoong OK'd to test tapeworm med against virusChina's Sinovac kicked off a coronavirusvaccine trial in Indonesia and revealed promising data on its candidate from a mid-stage study. South Korea's Daewoong Pharmaceutical got a thumbs up to test a2020/8/10
-
Amid COVID deal spree, Catalent plots Argentina manufacturing scale-upAmid a slew of COVID-19 vaccine pacts, Catalent is looking to expand its manufacturing power to churn out more drugsfor a wholly different set of diseases. Set to go live in late2021, a revamped site2020/8/7
-
AstraZeneca takes COVID-19 vaccine to China with BioKangtai deal for 200M-dose capacity by 2021We pointed out last week that China was a notablemissing elementin AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That has changed. AstraZenecareached a2020/8/6
-
GlaxoSmithKline jumps into myeloma with 'homemade' anti-BCMA drug BlenrepBack in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP of Oncology R&D, puts it. Thos2020/8/6
-
Takeda hustles to prevent cancer drug shortage after FDA warning letterTakeda took a slap from the FDA in June when inspectors slammed its Hikari, Japan, plant in a warning letter. It turns out that fixing those problems helped triggera local shortage of the chemotherap2020/8/5
-
Regeneron rises on Eylea, Dupixent strength as COVID-19 antibody funding pours inIn stark contrast to many drugmakers registeringsecond-quarter declines, Regeneron pulled off a 24% revenue increase on the strength of Eylea and Dupixent sales, as well as a U.S. government supply d2020/8/5
-
Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping dataIf Pfizer wants targeted lung cancer med Lorbrena to be a true follow-up to Xalkori, it has to get the product cleared in previously untreated ALK-positive patients. And it just took a step toward ac2020/8/4